MedPage Today: Support for Naltrexone-Bupropion for Long-term Weight Management in Selected Patients The European Medicines Agency (EMA) has concluded a review of the weight loss drug naltrexone/bupropion (Mysimba), which was prompted by concerns about potential long-term cardiovascular risks. The ... Weight loss medications can be an effective option for people struggling to lose weight through diet and exercise alone.

Context Explanation

Contrave (naltrexone and bupropion) and Wegovy (semaglutide) are two ... “Real-world data demonstrates that [naltrexone-bupropion] is as effective and safe in this population as in surgery-naive patients. Additionally, this effect was independent of dose, which could make ... A study by Ethan Lazarus, MD, in Obesity Pillars presents a comprehensive review of the appropriate use of the fixed-dose, extended-release combination of naltrexone and bupropion (NB-ER) for the ...

Insight Material

MedPage Today: Ethan Lazarus on Naltrexone/Bupropion for Primary Care Treatment of Obesity It’s common knowledge that managing your weight keeps you healthy now and as you get older. In fact, obesity contributes to several health conditions, including heart disease, stroke, type 2 diabetes ... Add Yahoo as a preferred source to see more of our stories on Google. Many medications that are commonly referred to as “weight loss drugs” are not actually FDA-approved for this purpose. One of the ...

Final Conclusion